Navigation Links
Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib
Date:9/2/2008

IBIS-2 (Integrated Biomarker and Imaging Study) Results Demonstrate

Benefits of VH(R) IVUS in Drug Development

SAN DIEGO, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC) [ESC Booth # A2-D403], a leading manufacturer of intravascular ultrasound (IVUS) and functional measurement (FM) technology, announced today the use of its VH(R) IVUS (Virtual Histology IVUS) in GlaxoSmithKline's IBIS-2 trial (Integrated Biomarker and Imaging Study). In the study, Volcano's VH(R) IVUS technology demonstrated and quantified compositional changes in atherosclerotic plaque that occurred over time. In IBIS-2, VH(R) IVUS showed compositional changes in the placebo group that suggest continued progression of necrotic core despite standard of care therapy. Use of the novel Lp-PLA2 inhibitor, darapladib, plus standard of care therapy prevented this progression. VH(R) IVUS is a catheter-based technology that creates colorized tissue maps of plaque composition in real-time.

Despite remarkable advances in diagnosis and therapy, atherosclerotic cardiovascular disease (CVD) is the number one killer of men and women in the Western world. Principal manifestations of atherosclerotic cardiovascular disease are heart disease and stroke. Atherosclerosis is the underlying mechanism for coronary artery disease, ischemic strokes, and peripheral vascular disease. Although a number of factors contribute to CVD, elevated plasma levels of Lp-PLA2 (lipoprotein-associated phospholipase A2) are associated with an increased risk.

"The results of IBIS-2 indicated that many coronary vessels with mild angiographic disease have large atherosclerotic plaques, which can be identified by VH(R) IVUS. The ability to character
'/>"/>

SOURCE Volcano Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Image Guided Radiation Therapy in Latham, NY. Now Fighting Cancer Using Fast and Precise RapidArc(TM) Radiotherapy Technology
2. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
3. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
4. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
5. First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval
6. Dr. Ari Kiev to be Featured Speaker at Biotechnology Conference Wall Street Unplugged: The Trout Group Investor Seminar in New York July 30
7. Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050
8. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
9. Modigene Platform Validated in Independent Phase III Trial of CTP Technology
10. Embryo Viability Studies Support Utility of Novel, Metabolomic Profiling Technology
11. GeoVax Reports Progress on Its AIDS Vaccine Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ... the "Dental Consumables Market - Global Industry ... - 2018" report to their offering. ... ) Dental consumables are products which are ... impairments, for tooth restoration and in treatment of ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading ... company, awarded several new IT value-added reseller (VAR) ... hospital organizations with IT goods and services at ... agreements, as well as value-added services such as ... New Novation agreements were awarded to ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 ... that it has waived the Office of Fair Trading (OFT) ... the outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM).   ... no longer conditional on OFT approval, and Shire expects to ... currently scheduled expiration time, subject to the satisfaction of all ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Reaffirms Primacy and Safety of ,First Generation, Antisense, ... (Nasdaq: GNTA ) announced the presentation of ... lead anticancer,compound, can be safely administered in high ... data were presented by Dr. Anthony Tolcher, Director,of ...
... - Studies Show Improvement in Hemodynamics and Delay ... Actelion Pharmaceuticals US, Inc.,today announced positive results from ... and effective as a combination therapy,for the treatment ... suggest that Tracleer, when given in combination with ...
Cached Medicine Technology:Genasense(R) Can be Administered by Brief High-Dose IV Infusion 2Genasense(R) Can be Administered by Brief High-Dose IV Infusion 3Genasense(R) Can be Administered by Brief High-Dose IV Infusion 4Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension 2Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension 3
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... Pharmaceuticals,Inc. (Nasdaq: CADX ), a biopharmaceutical company ... principally,for use in the hospital setting, today announced ... before the market opens on Tuesday, May 6,2008., ... and live webcast to,discuss the financial results and ...
... to Both Reduce Exacerbations ... and Improve Lung Function, ... and Drug Administration today approved Advair Diskus(R) 250/50,(fluticasone propionate 250 ... exacerbations in patients with chronic obstructive,pulmonary disease (COPD) who have ...
... Phase of NHLBI-Sponsored Study on Children,s Physical Activity in Child Care ... at Pediatric Academic Societies ... Annual Meeting, CINCINNATI, ... 3-6) are in child care centers, and growing concern over,childhood obesity has ...
... prolapse a tear or weakness in a womans pelvic ... the body runs in families, a new Saint Louis ... has had a hernia or prolapse two conditions that ... more likely to develop prolapse themselves, says Mary McLennan, M.D., ...
... April 30 NightHawk,Radiology Holdings, Inc. (Nasdaq: ... radiology groups and hospitals throughout the United States,today ... appointed as an,independent member of the company,s Board ... change, the company has regained compliance with the ...
... FOREST, Ill., April 30 Hospira, Inc.,(NYSE: HSP ... announced that Thomas E. Werner, senior vice president,Finance, and ... Bank of America 2008 Health Care Conference on Wednesday, ... Vegas., The presentation is scheduled to begin at ...
Cached Medicine News:Health News:Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008 2Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 2Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 3Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 4Health News:Flip Flops, Mulch and No Coat: Study Identifies Surprising Barriers to Outdoor Activity for Kids in Child-Care Centers 2Health News:Flip Flops, Mulch and No Coat: Study Identifies Surprising Barriers to Outdoor Activity for Kids in Child-Care Centers 3Health News:Flip Flops, Mulch and No Coat: Study Identifies Surprising Barriers to Outdoor Activity for Kids in Child-Care Centers 4Health News:Family history places women at risk of pelvic organ prolapse, SLU research finds 2Health News:NightHawk Radiology Holdings, Inc. Announces Appointment of David Engert to the Board of Directors 2Health News:NightHawk Radiology Holdings, Inc. Announces Appointment of David Engert to the Board of Directors 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: